Technology
Lifordi Is Pioneering a Targeted Approach to Enhance Delivery to the Immune System.
Lifordi is among the first companies to leverage the success of antibody-drug conjugates (ADC) to develop treatments for autoimmune and inflammatory disorders.
About
We Are Leading the Way in Developing Novel Treatments for Autoimmune Diseases.
Lifordi is a clinical-stage biotech company developing ADCs that target immune cells to treat autoimmune and inflammatory disorders with precision.
Spotlight
News
Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors
November, 2025